WO2000007579A3 - VERWENDUNG VON CYCLOPENTABENZOFURANDERIVATEN ZUR BEKÄMPFUNG VON NF-λB-ABHÄNGIGEN KRANKHEITEN - Google Patents

VERWENDUNG VON CYCLOPENTABENZOFURANDERIVATEN ZUR BEKÄMPFUNG VON NF-λB-ABHÄNGIGEN KRANKHEITEN Download PDF

Info

Publication number
WO2000007579A3
WO2000007579A3 PCT/EP1999/005426 EP9905426W WO0007579A3 WO 2000007579 A3 WO2000007579 A3 WO 2000007579A3 EP 9905426 W EP9905426 W EP 9905426W WO 0007579 A3 WO0007579 A3 WO 0007579A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclopentabenzofuran
derivatives
diseases
combating
dependent diseases
Prior art date
Application number
PCT/EP1999/005426
Other languages
English (en)
French (fr)
Other versions
WO2000007579A2 (de
Inventor
Matthias Gehling
Joerg Baumgarten
Axel Kretschmer
Horst-Peter Antonicek
Peter Proksch
Bambang W Nugroho
Frank Bohnenstengel
Original Assignee
Bayer Ag
Matthias Gehling
Joerg Baumgarten
Axel Kretschmer
Antonicek Horst Peter
Peter Proksch
Bambang W Nugroho
Frank Bohnenstengel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Matthias Gehling, Joerg Baumgarten, Axel Kretschmer, Antonicek Horst Peter, Peter Proksch, Bambang W Nugroho, Frank Bohnenstengel filed Critical Bayer Ag
Priority to US09/762,448 priority Critical patent/US6518274B1/en
Priority to AU57290/99A priority patent/AU5729099A/en
Priority to EP99944303A priority patent/EP1102585A2/de
Publication of WO2000007579A2 publication Critical patent/WO2000007579A2/de
Publication of WO2000007579A3 publication Critical patent/WO2000007579A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Cyclopentabenzofuran-Derivaten der Formel (I) zur Herstellung eines Arzneimittels zur Behandlung von Nuclear Faktor λB-abhängigen Krankheiten, insbesondere zur Behandlung von Entzündungskrankheiten, immunologisches Erkrankungen, septischem Schock, Transplantatabstossung, Strahlungsschäden, Reperfusionsverletzungen nach Ischämie, Thrombosen oder komplexen, chronisch-entzündlichen Erkrankungen wie Arteriosklerose sowie Asthma, Arthritis, Rheuma, Psoriasis und Krebs.
PCT/EP1999/005426 1998-08-05 1999-07-29 VERWENDUNG VON CYCLOPENTABENZOFURANDERIVATEN ZUR BEKÄMPFUNG VON NF-λB-ABHÄNGIGEN KRANKHEITEN WO2000007579A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/762,448 US6518274B1 (en) 1998-08-05 1999-07-29 Use of cyclopentabenzofuran-derivatives for combating (NF-κB)-dependent diseases
AU57290/99A AU5729099A (en) 1998-08-05 1999-07-29 Use of cyclopentabenzofuran-derivatives for combating nf-KappaB-dependent diseases
EP99944303A EP1102585A2 (de) 1998-08-05 1999-07-29 Verwendung von cyclopentabenzofuranderivaten zur bekaempfung von nf-kb abhangigen krankheiten

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19835325.1 1998-08-05
DE19835325A DE19835325A1 (de) 1998-08-05 1998-08-05 Verwendung von Cyclopentabenzofuran-Derivaten zur Bekämpfung von NF-kB abhängigen Krankheiten

Publications (2)

Publication Number Publication Date
WO2000007579A2 WO2000007579A2 (de) 2000-02-17
WO2000007579A3 true WO2000007579A3 (de) 2000-09-08

Family

ID=7876512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/005426 WO2000007579A2 (de) 1998-08-05 1999-07-29 VERWENDUNG VON CYCLOPENTABENZOFURANDERIVATEN ZUR BEKÄMPFUNG VON NF-λB-ABHÄNGIGEN KRANKHEITEN

Country Status (5)

Country Link
US (1) US6518274B1 (de)
EP (1) EP1102585A2 (de)
AU (1) AU5729099A (de)
DE (1) DE19835325A1 (de)
WO (1) WO2000007579A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ866500A0 (en) * 2000-07-05 2000-08-03 Exgenix Operations Pty Ltd Therapeutic compounds and methods
US20040086896A1 (en) * 2001-04-19 2004-05-06 Julie Carman Polynucleotides and polypeptides associated with the NF-kB pathway
DE10158561A1 (de) * 2001-11-29 2003-06-12 Bayer Ag Neue Verwendung von Cyclopentabenzofuranen
WO2004041812A1 (en) * 2002-11-08 2004-05-21 The Government Of The State Of Sarawak, Malaysia Therapeutic compounds and methods
DE102004024504A1 (de) * 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
EP1693059A1 (de) * 2005-02-22 2006-08-23 Deutsches Krebsforschungszentrum Verwendung von Rocaglamidederivate als spezifischen NF-AT Inhibitoren für die Behandlung bestimmter entzündlicher Krankheiten
EP2189158A1 (de) 2008-11-20 2010-05-26 DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts Kombination aus Rocaglamid und Apoptose mit Substanzen zur Krebsbehandlung
WO2013016658A1 (en) * 2011-07-27 2013-01-31 The Ohio State University Research Foundation Silvestrol, silvestrol analogs and uses thereof
EP3071234A1 (de) 2013-11-22 2016-09-28 Deutsches Krebsforschungszentrum Übersetzungsinhibitoren in einer hochdosierten chemo- und/oder radiotherapie
WO2020086562A1 (en) * 2018-10-22 2020-04-30 Trustees Of Boston University Compositions and methods for inhibiting viral infection
CN115073407A (zh) * 2021-03-10 2022-09-20 上海中医药大学 一种具有合成致死性的药用组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539414A (en) * 1983-04-15 1985-09-03 King Ming L 1H-Cyclopenta[b]benzofuran derivative and its analog
WO1997008161A1 (fr) * 1995-08-28 1997-03-06 Terumo Kabushiki Kaisha Agent deprimant une fonction oncogenique
JPH1112279A (ja) * 1997-06-27 1999-01-19 Microbial Chem Res Found Ｒａｓ蛋白の阻害活性を有する新規なアグライアスタチン立体異性体とそれらの製造法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004284A1 (en) 1994-08-04 1996-02-15 Novartis Ag Insecticidal polycyclic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539414A (en) * 1983-04-15 1985-09-03 King Ming L 1H-Cyclopenta[b]benzofuran derivative and its analog
WO1997008161A1 (fr) * 1995-08-28 1997-03-06 Terumo Kabushiki Kaisha Agent deprimant une fonction oncogenique
JPH1112279A (ja) * 1997-06-27 1999-01-19 Microbial Chem Res Found Ｒａｓ蛋白の阻害活性を有する新規なアグライアスタチン立体異性体とそれらの製造法

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CUI B ET AL: "Novel Cytotoxic 1H-Cyclopenta[b]benzofuran Lignans from Aglaia elliptica", TETRAHEDRON,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 53, no. 52, 29 December 1997 (1997-12-29), pages 17625 - 17632, XP004106528, ISSN: 0040-4020 *
DATABASE WPI Section Ch Week 199913, Derwent World Patents Index; Class B02, AN 1999-148553, XP002136960 *
DAVEY, ANDREW E. ET AL: "Synthesis of the novel anti-leukemic tetrahydrocyclopenta[b]benzofuran, rocaglamide and related synthetic studies", J. CHEM. SOC., PERKIN TRANS. 1 (1992), (20), 2657-66, XP000892004 *
DUMONTET V ET AL: "New Nitrogenous and Aromatic Derivatives from Aglaia argentea and A. forbesii", TETRAHEDRON,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 52, no. 20, 13 May 1996 (1996-05-13), pages 6931 - 6942, XP004103936, ISSN: 0040-4020 *
KING, MING LU ET AL: "X-ray crystal structure of rocaglamide, a novel antileukemic 1H-cyclopenta[b]benzofuran from Aglaia elliptifolia", J. CHEM. SOC., CHEM. COMMUN. (1982), (20), 1150-1, XP000892005 *
KO, FENG NIEN ET AL: "PAF antagonism in vitro and in vivo by aglafoline from Aglaia elliptifolia Merr", EUR. J. PHARMACOL. (1992), 218(1), 129-35, XP000905095 *
LEE, SANG KOOK ET AL: "Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica", CHEM.-BIOL. INTERACT. (1998), 115(3), 215-228, XP000905170 *
NAGAO, YOSHIMITSU ET AL: "One-pot synthesis of new 1,3-imidazolidines possessing three aryl groups via a 1,3-dipolar cycloaddition reaction", HETEROCYCLES (1994), 38(3), 587-93, XP000892007 *
OHSE, TAKUHITO ET AL: "Cyclopentabenzofuran Lignan Protein Synthesis Inhibitors from Aglaia odorata", J. NAT. PROD. (1996), 59(7), 650-652, XP000905082 *
WATANABE, TAKUMI ET AL: "Total synthesis of (.+-.)-aglaiastatin, a novel bioactive alkaloid", CHEM. COMMUN. (CAMBRIDGE) (1998), (10), 1097-1098, XP000892006 *
WU, TIAN-SHUNG ET AL: "Cytotoxic and Antiplatelet Aggregation Principles from Aglaia elliptifolia", J. NAT. PROD. (1997), 60(6), 606-608, XP000905066 *

Also Published As

Publication number Publication date
DE19835325A1 (de) 2000-02-10
AU5729099A (en) 2000-02-28
US6518274B1 (en) 2003-02-11
WO2000007579A2 (de) 2000-02-17
EP1102585A2 (de) 2001-05-30

Similar Documents

Publication Publication Date Title
WO2000007579A3 (de) VERWENDUNG VON CYCLOPENTABENZOFURANDERIVATEN ZUR BEKÄMPFUNG VON NF-λB-ABHÄNGIGEN KRANKHEITEN
MXPA04001889A (es) Inhibidores de la alquin-aril fosfodiesterasa-4.
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
LT3146969T (lt) Tepalas vietiniam psoriazės gydymui
RS109104A (en) Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity
WO2003049702A8 (en) Vanilloid receptor ligands and their use in treatments
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
PT3143995T (pt) Derivado de rapamicina para o tratamento do cancro de pulmão
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
BG103417A (en) Condensed pyrimidine bicyclic derivatives
SG149067A1 (en) IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT
CA2460939A1 (en) Substituted pyrazolyl compounds for the treatment of inflammation
HUP0200493A3 (en) Pharmaceutical compositions comprising sulphonyl-amino-carbonyl derivatives for the treatment of nuclear factor-kappa b mediated diseases
WO1994007479A3 (en) Immunopotentiatory agents
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
NZ508585A (en) Metabolites of ecteinascidin 743
WO2006017672A3 (en) 2, 8-disubstituted naphthyridine derivatives
AP8800106A0 (en) Substituted tetrarins chromans & related compounds in the treatment of asthma,arthritis etc.
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
CA2461567A1 (en) Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
CA2461622A1 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
AU1058492A (en) Improvements in or relating to organic compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999944303

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09762448

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999944303

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999944303

Country of ref document: EP